Clinical trials

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas

This is an expanded access program (EAP) for eligible participants designed to provide access to Dibotatug (DR-01). Physician-requested expanded access will generally only be considered for patients not otherwise eligible for an ongoing clinical study sponsored by Dren Bio and provided that other program eligibility criteria are also met.

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas